agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Key Inclusion Criteria:

• Relapsed/Refractory Multiple Myeloma

• Confirmed diagnosis and evidence of progressive disease or clinical relapse as defined by International Myeloma Working Group criteria and following prior therapy for multiple myeloma (MM)
• Relapsed or refractory MM requiring current treatment
• Previously failed ≥ 3 prior regimens (after at least 2 cycles of medication per regimen) and included at least 1 immunomodulatory drug, 1 proteasome inhibitor, and an anti-CD38 antibody agent
• Participants must have measurable disease as defined by at least 1 of the following:

• Serum M-protein ≥ 0.5 grams/deciliter (dL) by serum protein electrophoresis or for immunoglobulin A (IgA) myeloma, by quantitative IgA; or
• Urinary M-protein excretion at least 200 milligrams (mg)/24 hours; or
• Serum free light chain whereby the involved light chain measures ≥ 10 mg/dL and with an abnormal ratio
• Estimated life expectancy ≥ 3 months
• No other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the principal investigator

Key Exclusion Criteria:

• Concurrent invasive malignancy
• Participants who had an allogeneic stem cell transplantation and are still on immunosuppressive medications or corticosteroids above physiological dose within 4 weeks before agenT-797
• Prior radiotherapy within 2 weeks of start of study treatment
• Prior systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks prior to dose of study drug